Navigation Links
Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
Date:11/10/2008

Mooney Brings Wealth of Finance, Accounting and Industry Experience to

Kendle Board

CINCINNATI, Nov. 10 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the reappointment of Timothy M. Mooney to the Company's Board of Directors effective immediately. Mooney was Executive Vice President and Chief Financial Officer for Kendle from 1996 until his retirement in 2002, leading the Company's global financial operations, including finance, accounting, treasury, budgeting, taxes, mergers and acquisitions, investor relations and financial planning. He also served as a Director of the Company from 1997 to 2002. Mooney currently serves as Vice President of Operations at St. Xavier High School in Cincinnati. He brings nearly 40 years of accounting and finance experience to Kendle's Board and will serve as a member of the Audit Committee.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"We are thrilled to welcome back Tim Mooney to Kendle's Board," said Chairman and Chief Executive Officer Candace Kendle, PharmD. "Tim played a pivotal role in leading Kendle's financial operations during our early years as a private and then public company and our emergence as a global provider of CRO services, and we look forward to having the benefit of his experience with us once again as part of our Board. His extensive background in finance and accounting and knowledge of our sector will serve us well as Kendle continues to accelerate its position as a leading provider of Phase I-IV clinical development services to biopharmaceutical companies worldwide."

Prior to Kendle, Mooney served as Vice President, Treasurer and Chief Financial Officer for The Future Now, Inc. and Senior Vice President and Chief Financial Officer for Hook-SupeRx, Inc. His experience also includes serving as a Partner with the public accounting firm Coopers & Lybrand. He currently serves on the Board of Directors of Regent Communications, Inc., a publicly traded radio broadcasting company headquartered in Covington, Ky. He is Chairman of Regent's Audit Committee and is a member of the Nominating and Corporate Governance Committee. Mooney also has served on the Board of Directors of Winton Financial Corp., and as Chairman of Winton's Audit Committee and as a member of its Compensation Committee. Mooney earned a bachelor of science in business administration from Xavier University in Cincinnati.

Mooney's appointment increases the number of Kendle directors from seven to eight and the number of independent directors from five to six. He joins Dr. Kendle and current board members Christopher C. Bergen, Chief Operating Officer, Kendle; Robert R. Buck, President and Chief Executive Officer, Beacon Roofing Supply, Inc.; G. Steven Geis, PhD, M.D., Retired, Group Vice President: Arthritis, Cardiovascular and Oncology Clinical Development, Pharmacia & Upjohn Company; Donald C. Harrison, M.D., Senior Vice President and Provost for Health Affairs Emeritus, University of Cincinnati; Timothy E. Johnson, PhD, President, Johnson Investment Counsel, Inc. and Professor of Finance, University of Cincinnati; and Frederick A. Russ, PhD, Senior Vice Provost, University of Cincinnati.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has been recognized as "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Named a Best Place to Work in Greater Cincinnati
2. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
3. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
4. Kendle to Present at the UBS Global Life Sciences Conference
5. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
6. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
7. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
8. Kendle Appoints Patricia Williams Vice President, Commercial Operations
9. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
10. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
11. Kendle Leaders Adopt 10b5-1 Trading Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):